Mitra Biotech

mitrabiotech.com

Mitra Biotech is a global leader in advancing personalized cancer treatment. We are evolving the personalization of treatment selection and drug development through our phenotypic platforms that reliably predict individual response to tested treatment. Founded in 2010, Mitra is headquartered in Woburn, MA and maintains a significant research and laboratory presence in Bangalore, India. We are committed to developing new technologies that surpass existing biomarker-guided strategies for cancer treatment selection, expanding access to truly personalized medicine, and enhancing the clinical management of cancer.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDTECH

TO SEARCH FOR NEW TREATMENTS DISEASES, UW OSHKOSH PARTNERED WITH FAUNA BIO

Fauna Bio | April 01, 2022

news image

A biotechnology business pioneering comparative, computational, and translational genomics, Fauna Bio, announced collaboration with the University of Wisconsin OshKosh to speed the translation of human treatments identified via research into extreme mammal adaption. Fauna Bio's sponsorship of UW Oshkosh with $500,000 expands the University's capability for biomedical partnerships and helps promote the University as a destination for academics exploring innovative animal models and ...

Read More

MEDICAL

GT BIOPHARMA ANNOUNCES FDA DATA - GTB-3550, FOR TREATMENT OF HIGH-RISK MYELODYSPLASTIC SYNDROMES

GT Biopharma | December 23, 2020

news image

GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology organization focused in on innovative treatments dependent on the Company's restrictive NK cell engager (TriKE™) innovation stage is satisfied to report the introduction of extra interval information results for the Company's lead therapeutic competitor, GTB-3550, for the treatment of high-risk myelodysplastic syndromes (HR-MDS). Erica Warlick, M.D, Principal Investigator for the GTB-3550 clinical trial, i...

Read More

LIMINAL BIOSCIENCES EXPANDS R&D PIPELINE WITH NOVEL PRECLINICAL PROGRAM FOR EOSINOPHILIC-RELATED DISEASES

Liminal BioSciences Inc. | July 20, 2020

news image

Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that it has acquired all of the issued and outstanding shares in the capital of Fairhaven Pharmaceuticals Inc. ("Fairhaven"), thus acquiring a preclinical research program of small molecule antagonists. Investigational therapies developed in this program target a key chemoattractant and activator of eosinophils, wh...

Read More

MEDICAL

PFIZER COMPLETES ACQUISITION OF REVIRAL

Pfizer | June 10, 2022

news image

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV). ReViral brings to Pfizer a portfolio of promising therapeutic candidates, including sisunatovir, an orally administered inhibitor designed to block fusion of the RSV virus to the host cell. Sisunat...

Read More
news image

MEDTECH

TO SEARCH FOR NEW TREATMENTS DISEASES, UW OSHKOSH PARTNERED WITH FAUNA BIO

Fauna Bio | April 01, 2022

A biotechnology business pioneering comparative, computational, and translational genomics, Fauna Bio, announced collaboration with the University of Wisconsin OshKosh to speed the translation of human treatments identified via research into extreme mammal adaption. Fauna Bio's sponsorship of UW Oshkosh with $500,000 expands the University's capability for biomedical partnerships and helps promote the University as a destination for academics exploring innovative animal models and ...

Read More
news image

MEDICAL

GT BIOPHARMA ANNOUNCES FDA DATA - GTB-3550, FOR TREATMENT OF HIGH-RISK MYELODYSPLASTIC SYNDROMES

GT Biopharma | December 23, 2020

GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology organization focused in on innovative treatments dependent on the Company's restrictive NK cell engager (TriKE™) innovation stage is satisfied to report the introduction of extra interval information results for the Company's lead therapeutic competitor, GTB-3550, for the treatment of high-risk myelodysplastic syndromes (HR-MDS). Erica Warlick, M.D, Principal Investigator for the GTB-3550 clinical trial, i...

Read More
news image

LIMINAL BIOSCIENCES EXPANDS R&D PIPELINE WITH NOVEL PRECLINICAL PROGRAM FOR EOSINOPHILIC-RELATED DISEASES

Liminal BioSciences Inc. | July 20, 2020

Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that it has acquired all of the issued and outstanding shares in the capital of Fairhaven Pharmaceuticals Inc. ("Fairhaven"), thus acquiring a preclinical research program of small molecule antagonists. Investigational therapies developed in this program target a key chemoattractant and activator of eosinophils, wh...

Read More
news image

MEDICAL

PFIZER COMPLETES ACQUISITION OF REVIRAL

Pfizer | June 10, 2022

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV). ReViral brings to Pfizer a portfolio of promising therapeutic candidates, including sisunatovir, an orally administered inhibitor designed to block fusion of the RSV virus to the host cell. Sisunat...

Read More